ADAP Adaptimmune Therapeutics plc

4.62
0  -3%
Previous Close 4.75
Open 4.76
Price To book 2.02
Market Cap 327.07M
Shares 70,795,000
Volume 254,515
Short Ratio 4.44
Av. Daily Volume 154,939

SEC filingsSee all SEC filings

  1. 8-K - Current report 17707552
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17707521
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17704985
  4. 8-K - Current report 17691788
  5. 8-K - Current report 17688657

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Further trials planned for 2H 2016
NY-ESO T-cell therapy
Ovarian cancer
Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Further trials planned for 1H 2017.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)

Latest News

  1. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
  2. Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
  3. Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
  4. 9:51 am Adaptimmune Therapeutics prices an underwritten public offering of 14.3 mln of its American Depositary Shares at $4.20 per ADS for gross proceeds of about $60.1 mln
  5. Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
  6. Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
  7. Coverage initiated on Adaptimmune Therapeutics by Wells Fargo
  8. ADAPTIMMUNE THERAPEUTICS PLC Financials
  9. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
  10. Edited Transcript of ADAP earnings conference call or presentation 13-Mar-17 12:00pm GMT
  11. Adaptimmune Broadens Executive Team
  12. Adaptimmune Broadens Executive Team
  13. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  15. Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
  16. Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
  17. Q4 2016 Adaptimmune Therapeutics PLC Earnings Release - Before Market Open
  18. Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017
  19. Adaptimmune Therapeutics (ADAP) Jumps: Stock Rises 10.5%
  20. Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference